Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

被引：2
|
作者：
Chen, Ronald C.
Feuilly, Marion
Meng, Jie
Lister, Johanna
Marteau, Florence
Morris, Michael J.
George, Daniel J.
Choueiri, Toni K.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] IPSEN Pharma SAS, Boulogne, France
[3] Analyt LASER Intl, Lorrach, Germany
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Duke Univ, Durham, NC USA
[6] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4556
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)
    Shah, Ruchitbhai
    Botteman, Marc
    Solem, Caitlyn T.
    Luo, Linlin
    Doan, Justin
    Cella, David
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : 356 - +
  • [2] QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK
    Shah, R.
    Botteman, M.
    Kwon, Y.
    Gooden, K. M.
    Cella, D.
    Motzer, R.
    VALUE IN HEALTH, 2019, 22 : S106 - S106
  • [3] Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
    George, Daniel J.
    Hessel, Colin
    Halabi, Susan
    Michaelson, M. Dror
    Hahn, Olwen
    Walsh, Meghara
    Picus, Joel
    Small, Eric J.
    Dakhil, Shaker
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    Morris, Michael J.
    Choueiri, Toni K.
    ONCOLOGIST, 2019, 24 (11): : 1497 - 1501
  • [4] Avelumab plus axitinib (Ave plus Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
    Venugopal, B.
    Choueiri, T. K.
    Penkov, K. D.
    Albiges, L.
    Uemura, H.
    Larkin, J.
    Tomita, Y.
    Wang, J.
    Hoffman, J.
    Gerhold-Ay, A.
    Kieslich, P.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1017 - S1018
  • [5] Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
    Lee, Chung-Han
    Wan, Yin
    Smith, Alan
    Xie, Ran
    Motzer, Robert J.
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 31 : 1 - 9
  • [6] Quality-adjusted time without symptoms or toxicity (Q-TWiST) for lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma
    Lee, C. H.
    Wan, Y.
    Smith, A.
    Xie, R.
    Motzer, R. J.
    ONKOUROLOGIYA, 2021, 17 (04): : 54 - 64
  • [7] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    Choueiri, Toni K.
    Halabi, Susan
    Sanford, Ben L.
    Hahn, Olwen
    Michaelson, M. Dror
    Walsh, Meghara K.
    Feldman, Darren R.
    Olencki, Thomas
    Picus, Joel
    Small, Eric J.
    Dakhil, Shaker
    George, Daniel J.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 591 - +
  • [8] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC).
    Lee, Chung-Han
    Wan, Yin
    Smith, Alan D.
    Xie, Ran
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma
    Beaumont, Jennifer L.
    Salsman, John M.
    Diaz, Jose
    Deen, Keith C.
    McCann, Lauren
    Powles, Thomas
    Hackshaw, Michelle D.
    Motzer, Robert J.
    Cella, David
    CANCER, 2016, 122 (07) : 1108 - 1115
  • [10] Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).
    Shah, Ruchit
    Botteman, Marc
    Solem, Caitlyn
    Luo, Linlin
    Doan, Justin
    Cella, David
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345